Breast Surgery Division, European Institute of Oncology, Milano, Italy.
Epidemiology and Biostatistics Division, European Institute of Oncology, Milano, Italy.
Radiother Oncol. 2017 Jan;122(1):37-44. doi: 10.1016/j.radonc.2016.12.021. Epub 2017 Jan 4.
BACKGROUND AND PURPOSE: Whole breast radiotherapy (WBRT) is one of the possible reasons for the low rate of axillary recurrence after breast-conserving surgery (BCS). PATIENTS AND METHODS: We retrospectively collected data from 4,129 consecutive patients with breast cancer ⩽2cm and negative sentinel lymph node who underwent BCS between 1997 and 2007. We compared the risk of axillary lymph node recurrence between patients treated by WBRT (n=2939) and patients who received partial breast irradiation (PBI; n=1,190) performed by a single dose of electron intraoperative radiotherapy. RESULTS: Median tumour diameter was 1.1cm in both WBRT and PBI. Women who received WBRT were significantly younger and expressed significantly more multifocality, extensive in situ component, negative oestrogen receptor status and HER2 over-expression than women who received PBI. After a median follow-up of 8.3years, 37 and 28 axillary recurrences were observed in the WBRT and PBI arm, respectively, corresponding to a 10-year cumulative incidence of 1.3% and 4.0% (P<0.001). Multivariate analysis resulted in a hazard ratio of 0.30 (95% CI 0.17-0.51) in favour of WBRT. CONCLUSIONS: In this large series of women with T1 breast cancer and negative sentinel lymph node treated by BCS, WBRT lowered the risk of axillary recurrence by two thirds as compared to PBI.
背景与目的:全乳放疗(WBRT)是保乳手术后(BCS)腋窝复发率低的可能原因之一。
患者与方法:我们回顾性地收集了 1997 年至 2007 年间接受 BCS 的 ⩽2cm 且前哨淋巴结阴性的连续 4129 例乳腺癌患者的数据。我们比较了接受 WBRT(n=2939)和接受单次电子术中放疗(PBI)的患者的腋窝淋巴结复发风险。
结果:WBRT 和 PBI 的中位肿瘤直径均为 1.1cm。接受 WBRT 的患者明显比接受 PBI 的患者年轻,且多灶性、广泛原位成分、雌激素受体阴性和 HER2 过表达的比例明显更高。中位随访 8.3 年后,WBRT 和 PBI 组分别观察到 37 例和 28 例腋窝复发,10 年累积发生率分别为 1.3%和 4.0%(P<0.001)。多变量分析显示,WBRT 组的风险比为 0.30(95%CI 0.17-0.51)。
结论:在本系列接受 BCS 的 T1 期乳腺癌且前哨淋巴结阴性的大量女性患者中,与 PBI 相比,WBRT 使腋窝复发的风险降低了三分之二。
Zhonghua Zhong Liu Za Zhi. 2018-5-23
Curr Treat Options Oncol. 2024-12
Breast Cancer Res Treat. 2021-7